BRKR — Bruker Corporation stock price, charts and financials

QT77Bruker Corporation

Bruker Corporation (NASDAQ: BRKR) is a Healthcare company in the Medical - Devices industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
56.84
+0.53+0.93%
OverviewShort InterestFilings
BRKRQT77Bruker Corporation·NASDAQ
56.84+0.93%
News
Up 0.9% — Bruker Announces Majority Investment in MIMETAS to Advance Human Physiology-Relevant Drug Discovery and Development (gurufocus.com).
Medium confidence
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
MASI+0.00%$179.95BIO+0.21%$355.30PODD+0.42%$143.44GKOS+0.66%$182.62GMED-0.45%$85.76ALGN-1.17%$173.97SNN-0.12%$30.05PEN+0.21%$326.66
Snapshot
Index-P/E-EPS (ttm)-0.70Insider Own36.11%Shs Outstand152.23MPerf Week-12.42%
Market Cap8.57BForward P/E23.36EPS next Y2.41Insider Trans-0.02%Shs Float103.62MPerf Month-6.23%
Enterprise Value10.30BPEG-EPS next Q0.42Inst Own-Short Float14.12%Perf Quarter27.54%
Income-72.00MP/S2.45EPS this Y403.32%Inst Trans-Short Ratio5.89Perf Half Y34.32%
Sales3.50BP/B3.54EPS next Y13.58%ROA-1.18%Short Interest14.63MPerf YTD19.55%
Book/sh15.89P/C46.34EPS next 5Y13.35%ROE-2.92%52W High65.91 -13.75%Perf Year80.74%
Cash/sh1.22P/FCF57.70EPS past 3/5Y-ROIC2.56%52W Low28.80 97.41%Perf 3Y-16.59%
Dividend Est.0.20 (0.35%)EV/EBITDA41.55Sales past 3/5Y10.74% 11.57%Gross Margin46.69%Volatility6.24% 5.14%Perf 5Y-31.73%
Dividend TTM0.20 (0.35%)EV/Sales2.94EPS Y/Y TTM-192.11%Oper. Margin3.61%ATR (14)3.56Perf 10Y126.00%
Dividend Ex-DateJun 22, 2026Quick Ratio0.92Sales Y/Y TTM3.98%Profit Margin-2.03%RSI (14)47.68Recom2.55
Dividend Gr. 3/5Y0.00% 4.56%Current Ratio1.85EPS Q/Q53.12%SMA20-4.13%Beta1.22Target Price53.00
Payout-102.95%Debt/Eq0.81Sales Q/Q5.27%SMA50-3.60%Rel Volume0.96Prev Close56.32
Employees11,085LT Debt/Eq0.79EarningsNov 02SMA20021.65%Avg Volume2.59MPrice56.84
IPO DateAug 04, 2000Option/ShortYes / YesEPS/Sales Surpr.27.32% -1.77%Net Debt/EBITDA6.99Volume2,482,681Change0.93%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-05-26ReiteratedStifel NicolausHold$45 → $50
Jun-29-26ReiteratedGuggenheimBuy$58 → $70
Jun-24-26ReiteratedUBSNeutral$53 → $60
May-08-26ReiteratedStifel NicolausHold$40 → $45
May-07-26ReiteratedUBSNeutral$49 → $45
May-07-26ReiteratedBarclaysOverweight$50 → $53
Feb-13-26ReiteratedUBSNeutral$43 → $49
Feb-13-26ReiteratedGoldman SachsSell$40 → $35
Feb-13-26ReiteratedBarclaysOverweight$55 → $50
Feb-12-26ReiteratedJefferiesBuy$55 → $50
Latest News
Aug-10-26
Aug-10-2608:00AM
Bruker Announces Majority Investment in MIMETAS to Advance Human Physiology-Relevant Drug Discovery and Developmentgurufocus.com
Aug-04-26
Aug-04-2609:31PM
Bruker Corporation Q2 2026 Earnings Call SummaryYahoo
01:30PM
Bruker Corporation (BRKR) Q2 2026 Earnings Call Transcriptseekingalpha.com
12:16PM
Dow, S&P 500 Climb to Fresh Record Highsschaeffersresearch.com
11:31AM
Bruker (BRKR) Q2 Earnings: Taking a Look at Key Metrics Versus Estimateszacks.com
11:06AM
Bruker Q2 Earnings Call Highlightsmarketbeat.com
09:26AM
Bruker (BRKR) Q2 Earnings Beat Estimateszacks.com
08:00AM
Bruker Reports Second Quarter 2026 Financial Resultsgurufocus.com
Jul-31-26
Jul-31-2604:13AM
Dimensional Fund Advisors LP Grows Position in Bruker Corporation $BRKRdefenseworld.net
Jul-28-26
Jul-28-2607:47PM
Bruker Corp (BRKR) Stock Up 4.8% and Still Undervalued -- GF Score: 86/100gurufocus.com
03:15AM
Bank of New York Mellon Corp Decreases Stake in Bruker Corporation $BRKRdefenseworld.net
01:30AM
The London Company QTD Mid Cap Q2 2026 Contributors, Detractors And TradesSeekingAlpha
Jul-27-26
Jul-27-2604:45AM
First Trust Advisors LP Has $53.93 Million Holdings in Bruker Corporation $BRKRdefenseworld.net
04:13AM
California Public Employees Retirement System Sells 51,544 Shares of Bruker Corporation $BRKRdefenseworld.net
Jul-24-26
Jul-24-2604:01PM
Bruker Announces Date and Time of Second Quarter 2026 Earnings Release and Webcastbusinesswire.com
Company

Bruker Corporation stands as a prominent global developer, manufacturer, and distributor of cutting-edge scientific instruments, alongside comprehensive analytical and diagnostic solutions. Its operations are structured across three distinct segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. The company's extensive portfolio for life sciences encompasses a variety of advanced tools, including single and multi-modality systems, sophisticated mass spectrometry platforms, and critical diagnostic solutions. These diagnostics feature the acclaimed MALDI Biotyper for swift pathogen identification, various molecular diagnostic kits (such as genotype and fluorotype offerings), DNA test strips, and fluorescence-based polymerase chain reaction (PCR) technology, notably including SARS-CoV-2 testing solutions for COVID-19 diagnosis and Fluorotyper-SARS-CoV-2 plus kits. Beyond life science, Bruker delivers a wide array of specialized instruments for research, analysis, and process control. This includes portable analytical and bioanalytical detection systems, a full range of X-ray instruments (from analytical tools for electron microscopes to handheld, portable, and mobile X-ray fluorescence spectrometry devices), and sophisticated atomic force microscopy (AFM) instrumentation for non-contact nanometer resolution topography. Furthermore, it supplies automated X-ray metrology, automated AFM defect-detection, and equipment for photomask repair and cleaning. The company also excels in advanced optical fluorescence microscopy and provides critical products and services supporting multi-omics research for drug and biomarker discovery. Within its energy sector, Bruker is a key provider of superconducting materials, particularly metallic low-temperature superconductors, and develops complex tools and devices utilizing these materials, alongside other high-technology tools like synchrotron and beamline instrumentation. Reflecting its commitment to innovation, Bruker Corporation collaborates with Newomics Inc. on an LC-MS platform specifically tailored for drug discovery applications. Established in 1991, the corporation maintains its headquarters in Billerica, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue3,5003,4373,366——————
Cost of Goods Sold Incl. D&A1,8661,8591,717——————
Gross Profit1,6331,5781,650——————
Selling, General and Administrative Excl. Other971947894——————
Research and Development393395377——————
Other Operating Expense1420125——————
Operating Income127236253——————
Interest Expense436048——————
Unusual Expense
—————————
Non-Operating Income (Expense)-111-1550——————
Net Income Before Taxes-2921205——————
Income Taxes412991——————
Consolidated Net Income-72-9113——————
Net Income From Continuing Operations-68-8114——————
Net Income-72-9113——————
EPS (Recurring)-0.70-0.150.76——————
EPS (Basic, Before Extraordinaries)-0.70-0.150.76——————
EPS (Diluted)-0.70-0.150.76——————
EBITDA248303439——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio——77.13——————
Price To Sales Ratio2.472.082.59——————
Gross Margin46.6645.9149.02——————
Operating Margin3.636.877.52——————
Net Margin-2.06-0.263.36——————
Shares Outstanding152152149——————
Market Capitalization8,6407,1618,734——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$69.59$58.22$46.85$35.47$24.10● Close Price0.00M0.54M1.08M1.62M2.16MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Munch MarkEXEC VP&PRES BRUKER NANO INC.Jul 15 '26Option Exercise22.192,00044,380130,443Jul 16
Munch MarkEXEC VP&PRES BRUKER NANO INC.Jul 15 '26Sale60.252,000120,500128,443Jul 16
Munch MarkEXEC VP&PRES BRUKER NANO INC.Jun 15 '26Option Exercise22.192,00044,380130,443Jun 16
Munch MarkEXEC VP&PRES BRUKER NANO INC.Jun 15 '26Sale54.762,000109,520128,443Jun 16
Munch MarkEXEC VP&PRES BRUKER NANO INC.May 15 '26Option Exercise22.192,00044,380130,443May 18
Munch MarkEXEC VP&PRES BRUKER NANO INC.May 15 '26Sale43.902,00087,800128,443May 18
Munch MarkEXEC VP&PRES BRUKER NANO INC.Apr 15 '26Option Exercise22.192,00044,380130,443Apr 16
Munch MarkEXEC VP&PRES BRUKER NANO INC.Apr 15 '26Sale39.902,00079,800128,443Apr 16
Munch MarkEXEC VP&PRES BRUKER NANO INC.Mar 13 '26Option Exercise22.192,00044,380130,443Mar 16
Munch MarkEXEC VP&PRES BRUKER NANO INC.Mar 13 '26Sale35.442,00070,880128,443Mar 16
Munch MarkEXEC VP&PRES BRUKER NANO INC.Feb 13 '26Option Exercise22.192,00044,380130,443Feb 18
Munch MarkEXEC VP&PRES BRUKER NANO INC.Feb 13 '26Sale36.942,00073,880128,443Feb 18
Munch MarkEXEC VP&PRES BRUKER NANO INC.Jan 15 '26Option Exercise22.192,00044,380130,443Jan 16
Munch MarkEXEC VP&PRES BRUKER NANO INC.Jan 15 '26Sale49.202,00098,400128,443Jan 16
Munch MarkEXEC VP&PRES BRUKER NANO INC.Jan 12 '26Option Exercise22.197,000155,330135,443Jan 13
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.